Good point. They will probably gameplan their prep and try to cover as much of the Panel as possible.
Another area where that can come into play is if during oral argument, there is extensive discussion of the In re Cyclobenzaprine case, which is the most cited case in Amarin's Brief, and was Singer's case. Let's say that the generics butcher the application of that case, and leave an opening for Singer to say on rebuttal, "Appellees are wrong for the following reasons .... I know this to be true, as that was my case." Such a connection would have some extra juice coming from Singer.
News 
Market Data 
Discover 
